Potassium Bromide (KBroVet) for Canine Idiopathic Epilepsy: FDA Full Approval and Clinical Evidence

Bottom line.

• Potassium bromide (KBroVet, Toby's Canine Epilepsy) received FDA full approval in January 2026 for control of seizures in dogs with idiopathic epilepsy, providing veterinarians with the first fully approved bromide formulation in the US and supporting its established role as a first-line or add-on antiseizure medication.^1
• A 2024 clinician-focused review in Frontiers in Veterinary Science outlines bromide's dual role as both an effective antiseizure drug and a compound with a complex adverse effect profile - including bromism, polydipsia/polyuria, sedation, and hindlimb weakness - that requires structured therapeutic drug monitoring.^2
• A 2026 US retrospective study across Banfield Pet Hospitals (853 dogs with idiopathic epilepsy) found potassium bromide was the fourth most prescribed first-line antiseizure drug (11.1% of cases), with monitoring of serum bromide concentrations occurring in only 31.6% of cases - substantially below the 77.5% monitoring rate observed for phenobarbital.^3
• Bromide serum concentration monitoring is essential for both efficacy and safety management; therapeutic ranges and monitoring intervals should follow current specialist guidelines.^2
• Dietary chloride intake significantly affects bromide pharmacokinetics, as bromide and chloride compete for renal tubular reabsorption; clinicians should counsel owners that dietary changes can alter bromide levels and may precipitate toxicity or loss of seizure control.^2

Drug facts

• Class: Inorganic halide antiseizure medication; bromide ion
• Mechanism: Chloride channel stabilization - bromide substitutes for chloride at GABA-A and glycine receptor-associated chloride channels, enhancing inhibitory neurotransmission and raising the seizure threshold
• Route/interval: Oral (liquid or tablet); dosing interval is typically once or twice daily; dose individualized to serum concentration targeting
• Indication: Control of seizures in dogs with idiopathic epilepsy (KBroVet FDA full approval January 2026; NADA details per FDA CVM)
• Approval: FDA full approval January 2026; previously used off-label or under compounding in the US; established first-line/add-on role in ACVIM guidelines
• Label contraindications: Known bromide hypersensitivity; renal impairment (reduced bromide clearance); use caution in animals with hepatic disease
• Label common AEs: Sedation, ataxia, hindlimb weakness, polydipsia/polyuria/polyphagia, vomiting, bromism (chronic toxicity syndrome); pancreatitis association reported

A specific patient on potassium bromide?

Get an instant cited answer - no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=potassium-bromide-dogs-idiopathic-epilepsy

What the evidence shows

Mechanism and pharmacokinetics

Bromide is the oldest antiseizure medication with a documented clinical history in both human and veterinary medicine dating to the 19th century. As reviewed by Gouveia, Mandigers, and Cherubini (2024; PMID 38988980), bromide's antiseizure mechanism relies on its substitution for chloride at membrane channels, stabilizing inhibitory neurotransmission. Pharmacokinetically, bromide behaves as an inorganic ion: it distributes throughout total body water with a large volume of distribution relative to plasma, is not metabolized, and is excreted renally in competition with dietary chloride.

This competition with chloride is clinically important: diets high in chloride (for example, increased sodium chloride intake) accelerate bromide renal clearance, lowering serum levels and potentially reducing seizure control. Conversely, low-chloride diets slow bromide excretion, raising levels and risk of toxicity. Clinicians should counsel owners to maintain consistent diet formulations throughout bromide therapy and to notify the practice before any dietary change.

The long elimination half-life of bromide in dogs - typically ranging from 3 to 4 weeks - means steady-state is not reached for 2-3 months after initiating or changing doses, and serum monitoring should account for this kinetics.

Real-world prescribing in US primary care

Pompermaier et al. (2026; PMID 41737686) conducted a retrospective study across Banfield Pet Hospital electronic medical records (January 2020 to December 2023), identifying 853 dogs meeting strict criteria for idiopathic epilepsy. Prescribing patterns:

• Phenobarbital: most prescribed (34.9%)
• Levetiracetam (extended-release): 31.3%
• Zonisamide: 22.9%
• Potassium bromide: 11.1%

For potassium bromide, the study found the median maintenance daily dose was approximately 30 mg/kg, with once-daily administration in 83.3% of dogs. Therapeutic drug monitoring rates were notably lower for bromide (31.6%) compared to phenobarbital (77.5%), indicating an education and practice gap in bromide monitoring in primary care. The authors noted this variability highlights the need for updated evidence-based dosing guidelines.

Adverse effect profile and bromism

The Gouveia et al. 2024 review provides the most current synthesis of bromide's adverse effect profile for clinicians. The review characterizes bromism (chronic bromide toxicity) as the principal safety concern with long-term use, presenting as progressive neurological signs including sedation, ataxia, hindlimb weakness, confusion, and - in severe cases - stupor. Other adverse effects include polydipsia, polyuria, polyphagia, and gastrointestinal signs including vomiting.

Pancreatitis has been reported in association with bromide use, although the causal relationship is debated in the literature. Cats are more sensitive to bromide adverse effects than dogs, and bromide is not recommended in cats due to bronchopneumopathy risk.

The review discusses bromide's role within the current veterinary epilepsy treatment landscape, including its continued relevance as an add-on agent when phenobarbital or levetiracetam alone does not achieve seizure control, and its use as a first-line agent in dogs where phenobarbital is relatively contraindicated (for example, concurrent hepatic disease).

ACVIM context

The 2024 ACVIM Consensus Statement on management of status epilepticus and cluster seizures in dogs and cats (Charalambous et al., PMID 37921621) provides context for the role of bromide within the broader antiseizure medication hierarchy. While the consensus focuses on acute/emergency management, it reinforces the evidence base supporting established antiseizure medications including bromide as part of chronic background therapy.

How this fits clinical practice

Potassium bromide's 2026 FDA full approval (KBroVet) formalizes what has been a decades-long off-label use pattern in US veterinary practice. The approval does not change the fundamental pharmacology, but it provides veterinarians with a labeled formulation, a defined dosing framework, and product-specific adverse event reporting channels.

The clinical monitoring challenge with bromide - its long half-life, dietary chloride sensitivity, and slow approach to steady-state - means structured therapeutic drug monitoring is not optional. The Pompermaier 2026 real-world data showing only 31.6% monitoring rates suggest this is an area where clinical workflow improvement can directly affect patient safety.

Clinicians should communicate to owners before initiating therapy: the timeline to steady-state (approximately 3 months), the need for dietary consistency, the signs of bromism requiring immediate reassessment, and the requirement for regular serum monitoring. Voyage Clinical Desk can assist with monitoring interval calculations, steady-state timing estimates, and owner communication templates.

Voyage Clinical Desk

From clinical question to SOAP draft - cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=potassium-bromide-dogs-idiopathic-epilepsy

References

1. FDA Center for Veterinary Medicine. FDA grants full approval for drug to control seizures in dogs with idiopathic epilepsy (KBroVet). January 2026. https://www.fda.gov/animal-veterinary/cvm-updates/fda-grants-full-approval-drug-control-seizures-dogs-idiopathic-epilepsy
2. Gouveia D, Mandigers P, Cherubini GB. Bromide: the good, the bad, and the ugly of the oldest antiseizure medication. Front Vet Sci. 2024;11:1433191. https://pubmed.ncbi.nlm.nih.gov/38988980/
3. Pompermaier E, Morrison JA, Stabile F, De Risio L. Retrospective study on canine idiopathic epilepsy treatment in primary care practices in the United States. Front Vet Sci. 2026;13:1723038. https://pubmed.ncbi.nlm.nih.gov/41737686/
4. Charalambous M, Munana K, Patterson EE, Platt SR, Volk HA. ACVIM Consensus Statement on the management of status epilepticus and cluster seizures in dogs and cats. J Vet Intern Med. 2024;38(1):19-40. https://pubmed.ncbi.nlm.nih.gov/37921621/

Changelog

• 2026-06-09: First published.